Table 4.
Adverse events grade 2–4 during maintenance treatment.
| CTCAE grade n (%) | 2 | 3 | 4 |
|---|---|---|---|
| Hematologic AE | 5 (14) | 1 (3) | – |
| Anemia | 1 (3) | – | – |
| Thrombocytopenia | 1 (3) | 1 (3) | – |
| Neutropenia | 4 (11) | – | – |
| Non-hematologic AE | 14 (40) | 14 (40) | 2 (6) |
| Cardiac | 2 (6) | – | – |
| Central nervous system | 1 (3) | – | 1 (3) |
| Gastro-intestinal | 6 (17) | 3 (9) | 1 (3) |
| Infections | 8 (23) | 3 (9) | – |
| Infusion related reactions | – | – | – |
| Pain | 8 (23) | 1 (3) | – |
| Peripheral neuropathya | 4 (11) | – | – |
| Secondary primary malignancy | – | 3 (9) | – |
AEs of grade ≥3 that occurred in at least 5% of patients and AEs of special interest are reported.
a
Grade 1 peripheral neuropathy was observed in 3 (9%) patients.